ASP5834 / Astellas - LARVOL DELTA

Trial in progress: A phase 1 study of ASP5834 in patients with locally advanced or metastatic solid tumors with Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations or amplifications (ESMO 2026) - No abstract available

Metastases • P1 data • Preclinical • Oncology • Solid Tumor • KRAS

ASP5834, a novel pan-KRAS degrader, shows potent anti-tumor activity in KRAS mutant cancer models (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Oncology • KRAS

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=364 | Recruiting | Sponsor: Astellas Pharma Inc

Trial initiation date • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=364 | Recruiting | Sponsor: Astellas Pharma Inc

Trial initiation date • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

5834-CL-1001: A study to find a suitable dose of ASP5834 in adults with solid tumors (clinicaltrialsregister.eu) - P1 | N=70 | Recruiting | Sponsor: Astellas Pharma Inc.

New P1 trial • Oncology • Solid Tumor

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=364 | Recruiting | Sponsor: Astellas Pharma Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS